Skip to main content

Closed

CELU: Celularity Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-51.0% / yr

Operating margin-230.9%

ROIC-151.1%

Financially safe

Stretched

Debt / equity-1.07×

Interest coverage-9.1×

Current ratio0.15×

Celularity Inc.

CELUNASDAQ Capital Market·USD·Closed

Celularity Inc.

CELUNASDAQ·USD·Closed

$0.64

−6.57%

$0.64

−$0.04 (6.57%)

52W Range

2thpctl

Volume

0.50×avg

Mkt Cap

18.39MUSD

P/E

-0.2TTM

Div Yield

–ann

52W Range

2thpctl

Volume

0.50×avg

Market Cap

18.39MUSD

P/E Ratio

-0.2TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings